Bugs as drugs – Innovating in the Microbiome space

2025-05-06T12:41:28+01:006 May 2025|

We spoke to Dr Trevor Lawley, Senior Group Leader at the Wellcome Sanger Institute who works in the Parasites and Microbes Programme.  Trevor’s is the story of turning basic, fundamental research into innovative science with potential to treat a broad range of human diseases.

Microbiotica: CASE STUDY

2025-01-16T14:21:41+00:001 December 2024|

Based originally upon the research of the human microbiome carried out at the Wellcome Sanger Institute, Microbiotica was spun out as a microbiome therapeutics company in 2016. Today, Microbiotica is advancing steadily towards introducing transformational microbiome-based therapeutics and biomarkers in areas of high medical need, with first clinical trials – underpinned by a landmark £50m investment during 2022 – starting soon.